SHORTCUTS

December 2013   Clin Cancer Res. 2013. [Epub ahead of print] Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis Palmieri C, Fullarton JR, Brown J   Using a mixed treatment comparison, the efficacy of zoledronic acid was compared to other bisphosphonates (clodronate, pamidronate and ibandronate) in patients […]

Read More…

News and updates from www.palliativedrugs.com

Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website.   Hot topics Consultation on end of life care guidance The Leadership Alliance for the Care of Dying People (LACDP), set up in response to the recommendations from the independent report into the Liverpool Care Pathway (see news […]

Read More…

News and updates from www.palliativedrugs.com

Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website.   Safety updates EMA confirms metoclopramide restrictions The European Medicines Agency (EMA) has re-examined the recommended changes for metoclopramide in adults and children that it made in July 2013, following a request from one of the marketing authorization […]

Read More…

News and updates from www.palliativedrugs.com

Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website.   Safety updates EMA restricts metoclopramide dose and duration of use The European Medicines Agency (EMA) recommended changes to the dose and duration of use of metoclopramide in adults and children in July 2013, following a review. They […]

Read More…

News and updates from www.palliativedrugs.com

Selected items from the News and Latest Additions sections of www.palliativedrugs.com, the world’s leading palliative care website.   Safety updates Updated IV Ondansetron dosing for CINV The UK MHRA has given new guidance for the administration of IV ondansetron based on further information on the risk of dose-dependent QT interval prolongation, (first reported in August […]

Read More…